Loading…

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to hi...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2021-02, Vol.118 (5), p.1-8
Main Authors: Sasisekharan, Varun, Pentakota, Niharika, Jayaraman, Akila, Tharakaraman, Kannan, Wogan, Gerald N., Narayanasami, Uma
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3
cites cdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3
container_end_page 8
container_issue 5
container_start_page 1
container_title Proceedings of the National Academy of Sciences - PNAS
container_volume 118
creator Sasisekharan, Varun
Pentakota, Niharika
Jayaraman, Akila
Tharakaraman, Kannan
Wogan, Gerald N.
Narayanasami, Uma
description Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.
doi_str_mv 10.1073/pnas.2021615118
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7865175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>27006148</jstor_id><sourcerecordid>27006148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</originalsourceid><addsrcrecordid>eNpdkc1r3DAQxU1pabZpzz21CHLpxYkky7Z0KYSlSQOBQNP2KmR5vOvFllyNHNhr__LI3XT7cRrQ-81j9F6WvWX0nNG6uJicwXNOOatYyZh8lq0YVSyvhKLPsxWlvM6l4OIke4W4o5SqUtKX2UlRCFGVjK-yn3chbv3GOzOQfhxn5w2i2SPpfCA3m2tiXOwb3_aAJHpyf_nlPl_77zn_JWzAIQnwAGk7bk08WEB6wsk7BDIYjEga2HvXEkFGTyaPCRsGB4hkYeLr7EVnBoQ3T_M0-3b16ev6c357d32zvrzNrRBFzEtbSWWhNSXwrmBlBQ2rue2UUsLKVhXU2saIurS8pk0n2pYa06iOKtpwYFCcZh8PvtPcjNBacDGYQU-hH03Ya296_a_i-q3e-Addy5RVXSaDD08Gwf-YAaMee7QwDMaBn1FzUctSKioX9Ow_dOfnkEJeKJmKYLJmibo4UDZ4xADd8RhG9dKvXvrVf_pNG-___sOR_11oAt4dgB1GH456ioRWTMjiEQIZrbk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480001871</pqid></control><display><type>article</type><title>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>PubMed Central</source><creator>Sasisekharan, Varun ; Pentakota, Niharika ; Jayaraman, Akila ; Tharakaraman, Kannan ; Wogan, Gerald N. ; Narayanasami, Uma</creator><creatorcontrib>Sasisekharan, Varun ; Pentakota, Niharika ; Jayaraman, Akila ; Tharakaraman, Kannan ; Wogan, Gerald N. ; Narayanasami, Uma</creatorcontrib><description>Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.</description><identifier>ISSN: 0027-8424</identifier><identifier>ISSN: 1091-6490</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.2021615118</identifier><identifier>PMID: 33446512</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Adaptive immunity ; Adult ; Antibodies ; Antibodies, Viral - blood ; Antibody response ; Antigens ; Biological Sciences ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; Female ; Humans ; IgG antibody ; Illnesses ; Immune response ; Immune system ; Immunity ; Immunity, Humoral ; Immunoassay ; Immunoassays ; Immunoglobulin G ; Immunoglobulin G - blood ; Infections ; Longitudinal Studies ; Male ; Middle Aged ; Morbidity ; Neutralizing ; Nucleocapsids ; Pandemics ; Respiratory diseases ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccination ; Viral diseases</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2021-02, Vol.118 (5), p.1-8</ispartof><rights>Copyright © 2021 the Author(s). Published by PNAS.</rights><rights>Copyright National Academy of Sciences Feb 2, 2021</rights><rights>Copyright © 2021 the Author(s). Published by PNAS. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</citedby><cites>FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</cites><orcidid>0000-0002-0620-3189 ; 0000-0002-9663-0220</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/27006148$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/27006148$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33446512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sasisekharan, Varun</creatorcontrib><creatorcontrib>Pentakota, Niharika</creatorcontrib><creatorcontrib>Jayaraman, Akila</creatorcontrib><creatorcontrib>Tharakaraman, Kannan</creatorcontrib><creatorcontrib>Wogan, Gerald N.</creatorcontrib><creatorcontrib>Narayanasami, Uma</creatorcontrib><title>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.</description><subject>Adaptive immunity</subject><subject>Adult</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Biological Sciences</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>Female</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Illnesses</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunity</subject><subject>Immunity, Humoral</subject><subject>Immunoassay</subject><subject>Immunoassays</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Infections</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Neutralizing</subject><subject>Nucleocapsids</subject><subject>Pandemics</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2 - immunology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Vaccination</subject><subject>Viral diseases</subject><issn>0027-8424</issn><issn>1091-6490</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkc1r3DAQxU1pabZpzz21CHLpxYkky7Z0KYSlSQOBQNP2KmR5vOvFllyNHNhr__LI3XT7cRrQ-81j9F6WvWX0nNG6uJicwXNOOatYyZh8lq0YVSyvhKLPsxWlvM6l4OIke4W4o5SqUtKX2UlRCFGVjK-yn3chbv3GOzOQfhxn5w2i2SPpfCA3m2tiXOwb3_aAJHpyf_nlPl_77zn_JWzAIQnwAGk7bk08WEB6wsk7BDIYjEga2HvXEkFGTyaPCRsGB4hkYeLr7EVnBoQ3T_M0-3b16ev6c357d32zvrzNrRBFzEtbSWWhNSXwrmBlBQ2rue2UUsLKVhXU2saIurS8pk0n2pYa06iOKtpwYFCcZh8PvtPcjNBacDGYQU-hH03Ya296_a_i-q3e-Addy5RVXSaDD08Gwf-YAaMee7QwDMaBn1FzUctSKioX9Ow_dOfnkEJeKJmKYLJmibo4UDZ4xADd8RhG9dKvXvrVf_pNG-___sOR_11oAt4dgB1GH456ioRWTMjiEQIZrbk</recordid><startdate>20210202</startdate><enddate>20210202</enddate><creator>Sasisekharan, Varun</creator><creator>Pentakota, Niharika</creator><creator>Jayaraman, Akila</creator><creator>Tharakaraman, Kannan</creator><creator>Wogan, Gerald N.</creator><creator>Narayanasami, Uma</creator><general>National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0620-3189</orcidid><orcidid>https://orcid.org/0000-0002-9663-0220</orcidid></search><sort><creationdate>20210202</creationdate><title>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</title><author>Sasisekharan, Varun ; Pentakota, Niharika ; Jayaraman, Akila ; Tharakaraman, Kannan ; Wogan, Gerald N. ; Narayanasami, Uma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptive immunity</topic><topic>Adult</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Biological Sciences</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>Female</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Illnesses</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunity</topic><topic>Immunity, Humoral</topic><topic>Immunoassay</topic><topic>Immunoassays</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Infections</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Neutralizing</topic><topic>Nucleocapsids</topic><topic>Pandemics</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2 - immunology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Vaccination</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasisekharan, Varun</creatorcontrib><creatorcontrib>Pentakota, Niharika</creatorcontrib><creatorcontrib>Jayaraman, Akila</creatorcontrib><creatorcontrib>Tharakaraman, Kannan</creatorcontrib><creatorcontrib>Wogan, Gerald N.</creatorcontrib><creatorcontrib>Narayanasami, Uma</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasisekharan, Varun</au><au>Pentakota, Niharika</au><au>Jayaraman, Akila</au><au>Tharakaraman, Kannan</au><au>Wogan, Gerald N.</au><au>Narayanasami, Uma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2021-02-02</date><risdate>2021</risdate><volume>118</volume><issue>5</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>0027-8424</issn><issn>1091-6490</issn><eissn>1091-6490</eissn><abstract>Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>33446512</pmid><doi>10.1073/pnas.2021615118</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0620-3189</orcidid><orcidid>https://orcid.org/0000-0002-9663-0220</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8424
ispartof Proceedings of the National Academy of Sciences - PNAS, 2021-02, Vol.118 (5), p.1-8
issn 0027-8424
1091-6490
1091-6490
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7865175
source JSTOR Archival Journals and Primary Sources Collection; PubMed Central
subjects Adaptive immunity
Adult
Antibodies
Antibodies, Viral - blood
Antibody response
Antigens
Biological Sciences
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - immunology
Female
Humans
IgG antibody
Illnesses
Immune response
Immune system
Immunity
Immunity, Humoral
Immunoassay
Immunoassays
Immunoglobulin G
Immunoglobulin G - blood
Infections
Longitudinal Studies
Male
Middle Aged
Morbidity
Neutralizing
Nucleocapsids
Pandemics
Respiratory diseases
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike protein
Vaccination
Viral diseases
title Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A11%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Orthogonal%20immunoassays%20for%20IgG%20antibodies%20to%20SARS-CoV-2%20antigens%20reveal%20that%20immune%20response%20lasts%20beyond%204%20mo%20post%20illness%20onset&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Sasisekharan,%20Varun&rft.date=2021-02-02&rft.volume=118&rft.issue=5&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.2021615118&rft_dat=%3Cjstor_pubme%3E27006148%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2480001871&rft_id=info:pmid/33446512&rft_jstor_id=27006148&rfr_iscdi=true